These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 16321811)

  • 1. Enhancing siRNA effects in T cells for adoptive immunotherapy.
    Morris K; Castanotto D; Al-Kadhimi Z; Jensen M; Rossi J; Cooper LJ
    Hematology; 2005 Dec; 10(6):461-7. PubMed ID: 16321811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic.
    Eshhar Z
    Curr Opin Mol Ther; 2010 Feb; 12(1):55-63. PubMed ID: 20140817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer.
    Birkholz K; Hombach A; Krug C; Reuter S; Kershaw M; Kämpgen E; Schuler G; Abken H; Schaft N; Dörrie J
    Gene Ther; 2009 May; 16(5):596-604. PubMed ID: 19158846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive T-cell immunotherapy of cancer.
    Li Q; Chang AE
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):105-17. PubMed ID: 10515683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically engineered T-cells for adoptive immunotherapy.
    Pule M; Bollard CM; Heslop HE
    Curr Opin Mol Ther; 2002 Oct; 4(5):467-75. PubMed ID: 12435048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic modification of T lymphocytes for adoptive immunotherapy.
    Rossig C; Brenner MK
    Mol Ther; 2004 Jul; 10(1):5-18. PubMed ID: 15233937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma.
    Gonzalez S; Naranjo A; Serrano LM; Chang WC; Wright CL; Jensen MC
    J Gene Med; 2004 Jun; 6(6):704-11. PubMed ID: 15170741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dual role for genetically modified lymphocytes in cancer immunotherapy.
    Russo V; Bondanza A; Ciceri F; Bregni M; Bordignon C; Traversari C; Bonini C
    Trends Mol Med; 2012 Apr; 18(4):193-200. PubMed ID: 22230382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.
    Liu L; Sun M; Wang Z
    Cancer Lett; 2012 Mar; 316(1):1-5. PubMed ID: 22099879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
    Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
    Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic redirection of T cells for cancer therapy.
    Westwood JA; Kershaw MH
    J Leukoc Biol; 2010 May; 87(5):791-803. PubMed ID: 20179152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.
    Hombach A; Hombach AA; Abken H
    Gene Ther; 2010 Oct; 17(10):1206-13. PubMed ID: 20555360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Novel therapy for malignant lymphoma: adoptive immuno-gene therapy using chimeric antigen receptor(CAR)-expressing T lymphocytes].
    Ozawa K
    Nihon Rinsho; 2014 Mar; 72(3):547-52. PubMed ID: 24724418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. siRNA and cancer immunotherapy.
    Ghafouri-Fard S; Ghafouri-Fard S
    Immunotherapy; 2012 Sep; 4(9):907-17. PubMed ID: 23046235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adoptive immunotherapy using gene-modified T cells to express target-specific receptors against hematological malignancy].
    Fujiwara H
    Rinsho Ketsueki; 2014 Oct; 55(10):2162-74. PubMed ID: 25297783
    [No Abstract]   [Full Text] [Related]  

  • 17. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
    Spaapen R; van den Oudenalder K; Ivanov R; Bloem A; Lokhorst H; Mutis T
    Clin Cancer Res; 2007 Jul; 13(13):4009-15. PubMed ID: 17606735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
    Arakawa F; Shibaguchi H; Xu Z; Kuroki M
    Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer immunotherapy.
    Zhou J; Zhong Y
    Cell Mol Immunol; 2004 Aug; 1(4):247-55. PubMed ID: 16225767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.